A large national database study presented at CROI 2026 in Denver, CO, reports that 5-year survival remains lower for people with HIV compared with people without HIV across most treatment modalities for...
In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...
A type III hybrid effectiveness–implementation trial compared community-based organization versus direct-to-consumer delivery of the Keep It Up! digital HIV prevention intervention for young men who have...
A large cross-sectional Italian study evaluated the prevalence of cognitive frailty and identified HIV-specific and clinical risk factors among adults 50 years or older living with HIV, highlighting the...
In a large multicountry trial, researchers evaluated whether an integrase inhibitor–based regimen offers comparable or superior treatment outcomes to a boosted protease inhibitor regimen in adults with...
A national analysis presented at the 2025 AHA Scientific Sessions found that patients with HIV hospitalized with cardiac implantable electronic device–related infective endocarditis had significantly lower...
A new longitudinal study published in the Journal of the American Academy of Dermatology evaluated more than a decade of data from adults living with HIV, revealing a steady decline in dermatologic disease...
Managing HIV today means balancing speed, precision, and prevention. From deciding when to start antiretroviral therapy (ART) to optimizing follow-up labs and ensuring vaccine and prophylaxis coverage,...
